NASDAQ:TVRD

Tvardi Therapeutics Q2 2025 Earnings Results & Report

Tvardi Therapeutics logo
$1.04 +0.03 (+2.97%)
Closing price 04:00 PM Eastern
Extended Trading
$1.02 -0.02 (-2.31%)
As of 05:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tvardi Therapeutics missed analyst earnings expectations in its Q2 2025 results, released August 14, 2025. The company reported EPS of -$1.00 versus the -$0.51 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
After Market Closes

Tvardi Therapeutics EPS Results

Actual EPS
-$1.00
Consensus EPS
-$0.51
Beat/Miss
Missed by -$0.49
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 6 quarters

Tvardi Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Tvardi Therapeutics Q2 2025 Earnings FAQ

Tvardi Therapeutics (NASDAQ:TVRD) reported earnings of -$1.00 per share for Q2 2025, missing the consensus estimate of -$0.51. The report was announced on Thursday, August 14, 2025.

Tvardi Therapeutics Earnings Headlines

Buy Stocks… A Crash is Coming
Think stocks are expensive and a crash is coming? Economist Jim Rickards says you're right, but he urges investors not to sell before hearing his 2027 prediction. He warns that by November 30th, Congress is set to make a move he believes will trigger a historic buying panic. Economists call the phenomenon a crack-up boom. Rickards is known for correctly predicting the biggest market shocks of the last 20 years.tc pixel
See More Tvardi Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tvardi Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tvardi Therapeutics and other key companies, straight to your email.

About Tvardi Therapeutics

Tvardi Therapeutics (NASDAQ:TVRD) is a clinical-stage biopharmaceutical company developing treatments for cancer and fibrotic diseases. The company’s research focuses on STAT3, a protein involved in processes that can contribute to tumor growth and fibrosis.

Its lead drug candidate, TTI-101, is an oral small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors. Tvardi is also advancing additional drug candidates based on its STAT3 research platform.

Headquartered in The Woodlands, Texas, Tvardi is focused on research and clinical development; its investigational candidates are not established commercial products. The company was founded to develop therapies targeting STAT3.

View Tvardi Therapeutics Profile